Andrew K. Balo
Known title: *CIK: 0001323190
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
Transaction History
| GCTK | ▲ Buy | Grant | 1,285 | $0 | 10/3/2025 | View on chart |
| GCTK | ▲ Buy | Grant | 3,332 | $0 | 7/11/2025 | View on chart |
| GCTK | ▲ Buy | Grant | 4,490 | $0 | 3/26/2025 | View on chart |
| GCTK | ▲ Buy | Grant | 75 | $0 | 3/25/2025 | View on chart |
| DXCM | ▼ Sell | Other | 3,275 | $365K | 3/10/2023 | View on chart |
| DXCM | ▼ Sell | Other | 2,405 | $268K | 3/10/2023 | View on chart |
| DXCM | ▼ Sell | Other | 5,990 | $667K | 3/10/2023 | View on chart |
| DXCM | ▼ Sell | Other | 932 | $378K | 3/9/2022 | View on chart |
| DXCM | ▼ Sell | Other | 1,549 | $629K | 3/9/2022 | View on chart |
| DXCM | ▼ Sell | Other | 949 | $385K | 3/9/2022 | View on chart |
| DXCM | ▲ Buy | Grant | 4,984 | $5 | 3/8/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 1,248 | $676K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 273 | $148K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 200 | $109K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 50 | $27K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 550 | $301K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Other | 2,498 | $0 | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 15 | $8K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 1,261 | $693K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 750 | $411K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Other | 2,498 | $0 | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 1,200 | $660K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 50 | $28K | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
GCTK’s Lōkahi Expands Collaboration & Launches Qare
Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.
GCTK’s Lōkahi Expands Collaboration & Launches Qare. Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.